April 13 Bristol-Myers Squibb Co said on
Thursday it entered into a deal with Biogen Inc and
Roche Holding AG to license two of its drugs for an
upfront fee of $470 million.
Bristol will license its experimental neurodegenerative
disorder drug, BMS-986168, to Biogen for use in progressive
supranuclear palsy, which is characterized by brain cell damage.
Bristol's rare muscle-wasting disease drug, BMS-986089, will
be licensed by Roche for use in duchenne muscular dystrophy.
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by